Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

METACANCER

Financiado

Cerrado

Identification and validation of new breast cancer biomarkers based on integrate...

Identification and validation of new breast cancer biomarkers based on integrated metabolomics Breast cancer is the most common cancer in women. It is therefore in the focus of approaches for the identification of predictive molecular biomarkers. In contrast to transcriptomics, the changes in metabolite levels that are ass... ver más

31/03/2011

CHARITE UNIVERSIT...

4M€

Presupuesto del proyecto: 4M€

Líder del proyecto

CHARITE UNIVERSITAETSMEDIZIN BERLIN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 7 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2011-03-31 No tenemos la información de la convocatoria

0% 78% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

7 Participantes

CHARITE UNIVERSITAETSMEDIZI...

0.00€ | Lider

HIGHCHEM SRO

N.D. | Participante

VTT

N.D. | Participante

THE CHANCELLOR MASTERS AND S...

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

RTC-2016-5674-1 Determinación de perfiles metabolómicos en el diagnóstico pr... 482K€ Cerrado

FUTUGEMET Functional tumour genomics using metabolomic profiling 181K€ Cerrado

CTQ2016-80069-C2-1-R ONCOMETABOLITOS Y METALOFARMACOS NANOESTRUCTURADOS: DESARROL... 154K€ Cerrado

Metabonomics in NETs Evolving landscape of neuroendocrine tumor disease Predicti... 209K€ Cerrado

PID2021-126709OA-I00 ESTUDIOS METABOLOMICOS IN VIVO PARA EL DESCUBRIMIENTO Y VALI... 157K€ Cerrado

BIOSMALL Identification of subtype-specific biomarkers in small cell... Cerrado

Líder del proyecto

CHARITE UNIVERSITAETSMEDIZIN BERLIN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 4M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Breast cancer is the most common cancer in women. It is therefore in the focus of approaches for the identification of predictive molecular biomarkers. In contrast to transcriptomics, the changes in metabolite levels that are associated with tumor development and progression have not been investigated to a great extent, so far. Metabolomics is defined as the study of all metabolites in a cell, tissue or organism, and the metabolome is regarded as the amplified output of a biological system. The originality of the METAcancer approach will be the first-time application of combined technologies for metabolic profiling to large-scale analysis of patient samples in the field of translational research in breast cancer. We will test the hypothesis that alterations in the level of metabolites can be used for a molecular classification of breast cancer and for identification of new prognostic and predictive biomarkers. Our project is based on a large tumor biobank as well as on previous investigations of the consortium partners. We will use three different metabolic profiling technologies (GC-MS, NMR and LC-MS) to maximize the coverage of the breast cancer metabolome and apply advanced strategies for identification of individual metabolites. METAcancer’s integrated data-mining approach combines metabolomic data gained under the project with existing transcriptomic data pools for bioinformatic interpretation of cellular networks. By this strategy we will be able to go beyond the metabolite level and to identify and validate selected protein and mRNA biomarkers relevant for metabolic alterations. This will result in a combined signature consisting of metabolites as well as key protein and mRNA markers as a basis for a validated diagnostic system to assess prognosis and to guide targeted therapies in breast cancer.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores